Warfarin Patient Self-management Implementation in the US Healthcare System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-15

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the US, patients receiving warfarin therapy are rarely allowed to engage in patient self-management (PSM) which is less burdensome, less expensive, and safer than standard clinic-directed warfarin management. The long-term objective of our application is to improve the safety of ambulatory warfarin therapy through increasing the implementation of PSM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy

NCT00993200

Blood Clotting

COMPLETED PHASE4

Prospective Trial of a Validated Algorithm for Warfarin Dosing

NCT02705976

Anticoagulation

COMPLETED NA

Patient-Centered Anticoagulation Self-Monitoring in Minority Patients

NCT02776566

Thromboembolism Blood Coagulation Disorders Cardiovascular Disease +1 more

COMPLETED NA

Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients

NCT00810784

Venous Thromboembolism

COMPLETED

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

NCT00927862

Thromboembolism

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the US, patients receiving warfarin therapy are rarely allowed to engage in patient self-management (PSM) which is less burdensome, less expensive, and safer than standard clinician-directed warfarin management. National and international evidence-based guideline panels strongly recommend PSM over other warfarin management methods for appropriate patients because it improves INR control, cuts risk of thrombosis and death by half without increasing bleeding risk, and increases patient satisfaction and quality of life. The reasons behind PSM underutilization in US settings have not been systematically assessed and validated. We will address this knowledge gap and provide foundational information for increasing PSM utilization within the US healthcare system. Our Aim 1 will assess and validate barriers and facilitators to PSM and evaluate their applicability to the US healthcare system; Aim 2 will develop and test PSM implementation strategies in US ambulatory care sites using rapid-cycle research methodology; and Aim 3 will assess implementation (feasibility, fidelity, adoption), clinical (effectiveness, safety, equity, patient-centeredness), and end-user (satisfaction) outcomes. The long-term objective of our application is to improve the safety of ambulatory warfarin therapy through increasing the implementation of PSM. Our research proposal is guided by an implementation science logic model that incorporates well-known implementation science frameworks to support the specific aims. Qualitative data collection and analysis for Aim 1 will be organized using the Consolidated Framework for Implementation Research (CFIR) a determinant framework that identifies five domains influencing implementation: Intervention, Inner Setting, Outer Setting, Individuals, and the Implementation Process. Constructs within each domain provide guidance on factors to identify and measure as potential implementation barriers or facilitators. PSM implementation activities in Aim 2 will be guided by the Quality Implementation Framework (QIF), which identifies the critical implementation process steps and specific actions related to these steps that can be utilized to achieve quality PSM implementation. Implementation strategies will be supported by the rapid-cycle research framework developed by the AHRQ Practice Based Research Network. Implementation outcomes in Aim 3 will be structured using the well-known Reach, Efficacy, Adoption, Implementation, Maintenance (RE-AIM) framework. We will utilize a type III hybrid research design to test PSM implementation strategies while observing/gathering information on PSM-related clinical and economic outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Venous Thromboembolism Heart Valve Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Warfarin Patient Self-Management

Patients managing decisions relating to warfarin dose and next INR test based on the results of current INR test

Group Type EXPERIMENTAL

Patient self-management

Intervention Type OTHER

Patient makes independent decisions regarding warfarin therapy changes using warfarin dosing tools

Historical Control

Patients managed by anticoagulation providers prior to transitioning to warfarin patient self-management

Group Type ACTIVE_COMPARATOR

Usual care provided by anticoagulation providers

Intervention Type OTHER

Normal care provided by anticoagulation providers

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patient self-management

Patient makes independent decisions regarding warfarin therapy changes using warfarin dosing tools

Intervention Type OTHER

Usual care provided by anticoagulation providers

Normal care provided by anticoagulation providers

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 18 years of age treated with warfarin for any indication for at least 9 months prior to enrollment
* Demonstrate the willingness and ability to test their own INR using a home INR monitoring device or have same-day access to clinic-derived INR results (e.g., via electronic medical record secure messaging)
* Willing to make independent decisions about warfarin dosing based on INR results
* Able to perform INR tests at least every 2 weeks
* Currently have and willing to maintain internet access for the duration of the study in order to complete online data collection forms
* Have an anticipated duration of warfarin therapy of at least 6 months

Exclusion Criteria

* Goal INR range other than 2.0-3.0 or 2.5-3.5
* Known poor adherence to warfarin therapy
* Non-English speaking
* Inability or refusal to provide written informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No